Publications médicale

CAC 2015-2021

 

LARGILLIER Rémy

 

DPD status and fluoropyrimidines-based treatment: high activity matters too.

Chamorey E, Francois E, Etienne MC, Ferrero JM, Peyrade F, Barranger E, Bozec A, Largillier R, Cassuto O, Viotti J, Schiappa R, Milano G.

BMC Cancer. 2020 May 18;20(1):436. doi: 10.1186/s12885-020-06907-0.

PMID: 32423482

 

Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.

Lee CK, Asher R, Friedlander M, Gebski V, Gonzalez-Martin A, Lortholary A, Lesoin A, Kurzeder C, Largillier R, Hilpert F, Hardy-Bessard AC, Kaminsky MC, Poveda A, Pujade-Lauraine E.

Eur J Cancer. 2019 Aug;117:99-106. doi: 10.1016/j.ejca.2019.05.029. Epub 2019 Jul 3.

PMID:31279306

 

Iron deficiency during first-line chemotherapy in metastatic cancers: a prospective epidemiological study.

Saint A, Viotti J, Borchiellini D, Hoch B, Raimondi V, Hebert C, Largillier R, Evesque L, Follana P, Ferrero JM, Delaby C, Schiappa R, Chamorey E, Barriere J.

Support Care Cancer. 2020 Apr;28(4):1639-1647. doi: 10.1007/s00520-019-04938-3. Epub 2019 Jul 6.

PMID:31278463

 

Predicting early death in older adults with cancer.

Boulahssass R, Gonfrier S, Ferrero JM, Sanchez M, Mari V, Moranne O, Rambaud C, Auben F, Hannoun Levi JM, Bereder JM, Bereder I, Baque P, Turpin JM, Frin AC, Ouvrier D, Borchiellini D, Largillier R, Sacco G, Delotte J, Arlaud C, Benchimol D, Durand M, Evesque L, Mahamat A, Poissonnet G, Mouroux J, Barriere J, Benizri E, Piche T, Guigay J, Francois E, Guerin O.

Eur J Cancer. 2018 Sep;100:65-74. doi: 10.1016/j.ejca.2018.04.013. Epub 2018 Jun 29.

PMID: 30014882

 

[Expectation about maintenance therapy among the GINECO French ovarian cancer cohort from the European NOGGO/ENGOT-ov22 Expression IV survey].

Lorcet M, Lortholary A, Kurtz JE, Berton-Rigaud D, Fabbro M, De La Motte Rouge T, Kaminsky-Forrett MC, Floquet A, Freyer G, Combe P, Dohollou N, Kalbacher E, Despax R, Largillier R, Hardy Bessard AC, Gane N, Sehouli J, Oskay-Oezcelik G, Licaj I, Ray-Coquard I, Joly Lobbedez F.

Bull Cancer. 2018 May;105(5):465-474. doi: 10.1016/j.bulcan.2018.01.015. Epub 2018 Mar 12. French.

PMID:29544693

 

New advances in DPYD genotype and risk of severe toxicity under capecitabine.

Etienne-Grimaldi MC, Boyer JC, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C, Thomas F, Chatelut E, Merlin JL, Pinguet F, Ferrand C, Meijer J, Evrard A, Llorca L, Romieu G, Follana P, Bachelot T, Chaigneau L, Pivot X, Dieras V, Largillier R, Mousseau M, Goncalves A, Roché H, Bonneterre J, Servent V, Dohollou N, Château Y, Chamorey E, Desvignes JP, Salgado D, Ferrero JM, Milano G.

PLoS One. 2017 May 8;12(5):e0175998. doi: 10.1371/journal.pone.0175998. eCollection 2017.

PMID: 28481884

 

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.

Ferrero JM, Hardy-Bessard AC, Capitain O, Lortholary A, Salles B, Follana P, Herve R, Deblock M, Dauba J, Atlassi M, Largillier R.

Cancer. 2016 Oct 15;122(20):3119-3126. doi: 10.1002/cncr.30170.

PMID:27412268

 

[Adaptation and validation of a brief screening questionnaire of depressive disorders in patients with cancer: Q2i study].

Barriere J, Mari V, Cherikh F, Largillier R, Ettaiche M, Schiappa R, Chamorey E, Ferrero JM, Gal J.

Bull Cancer. 2016 Feb;103(2):138-47. doi: 10.1016/j.bulcan.2015.09.008. Epub 2015 Oct 23. French.

PMID: 26602270

 

Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer.

Rhondali W, Freyer G, Adam V, Filbet M, Derzelle M, Abgrall-Barbry G, Bourcelot S, Machavoine JL, Chomat-Neyraud M, Gisserot O, Largillier R, Le Rol A, Priou F, Saltel P, Falandry C.

Clin Interv Aging. 2015 Jul 13;10:1155-62. doi: 10.2147/CIA.S71690. eCollection 2015.

PMID: 26203235

 

Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH Study.

Gligorov J, Pivot XB, Jacot W, Naman HL, Spaeth D, Misset JL, Largillier R, Sautiere JL, de Roquancourt A, Pomel C, Rouanet P, Rouzier R, Penault-Llorca FM; Francilian Breast Intergroup.

Oncologist. 2015 Aug;20(8):873-9. doi: 10.1634/theoncologist.2014-0467. Epub 2015 Jun 25.

PMID: 26112003

 

Prognostic Factors in 401 Elderly Women with Metastatic Breast Cancer.

Follana P, Barrière J, Chamorey E, Largillier R, Dadone B, Mari V, Hannoun-Levi JM, Marcy M, Flipo B, Ferrero JM.

Oncology. 2014 Feb 26;86(3):143-151. [Epub ahead of print]

PMID: 24577186

 

A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.

Weber B, Largillier R, Ray-Coquard I, Yazbek G, Meunier J, Alexandre J, Dauba J, Spaeth D, Delva R, Joly F, Pujade-Lauraine E, Copel L; GINECO group, France.

Support Care Cancer. 2013 Jul;21(7):1947-54. doi: 10.1007/s00520-013-1748-0. Epub 2013 Feb 19.

PMID: 23420555

 

A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group.

Pautier P, Floquet A, Gladieff L, Bompas E, Ray-Coquard I, Piperno-Neumann S, Selle F, Guillemet C, Weber B, Largillier R, Bertucci F, Opinel P, Duffaud F, Reynaud-Bougnoux A, Delcambre C, Isambert N, Kerbrat P, Netter-Pinon G, Pinto N, Duvillard P, Haie-Meder C, Lhommé C, Rey A.

Ann Oncol. 2013 Apr;24(4):1099-104. doi: 10.1093/annonc/mds545. Epub 2012 Nov 8.

PMID: 23139262

 

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients.

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, Gebski V, Lauraine EP.

Br J Cancer. 2012 Aug 7;107(4):588-91. doi: 10.1038/bjc.2012.307. Epub 2012 Jul 26.

PMID: 22836511

 

BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.

Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL.

Ann Oncol. 2012 Nov;23(11):2799-805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5.

PMID:22771827

 

Self-management strategies adopted by breast cancer survivors to improve their adherence to tamoxifen.

Sarradon-Eck A, Pellegrini I, Largillier R, Duran S, Tallet A, Tarpin C, Julian-Reynier C.

Breast J. 2012 Jul-Aug;18(4):389-91. doi: 10.1111/j.1524-4741.2012.01258.x. Epub 2012 May 29.

PMID:22640035

 

A phase I study of UFT-oral vinorelbine in metastatic breast cancer.

Ferrero JM, Largillier R, Michel C, Amiot V, Milano G, Hébert C, Mari V, Courdi A, Figl A, Follana P, Barrière J, Chamorey E.

Oncology. 2011;81(2):73-8. Epub 2011 Sep 30.

PMID:21968516

 

A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, Alexandre J, Bourgeois H, Jaubert D, Paraiso D, Largillier R.

Breast Cancer Res Treat. 2012 Jan;131(1):127-35. Epub 2011 Sep 24.

PMID:21947680

 

Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO).

Lortholary A, Largillier R, Weber B, Gladieff L, Alexandre J, Durando X, Slama B, Dauba J, Paraiso D, Pujade-Lauraine E; GINECO group France.

Ann Oncol. 2012 Feb;23(2):346-52. Epub 2011 May 11.

PMID:21562072

 

Recommendations for a lifestyle which could prevent breast cancer and its relapse: physical activity and dietetic aspects.

Magné N, Melis A, Chargari C, Castadot P, Guichard JB, Barani D, Nourissat A, Largillier R, Jacquin JP, Chauvin F, Merrouche Y.

Crit Rev Oncol Hematol. 2011 Dec;80(3):450-9. Epub 2011 Feb 21.

PMID:21334920

 

Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy.

Guiu S, Liegard M, Favier L, van Praagh I, Largillier R, Weber B, Coeffic D, Moreau L, Priou F, Campone M, Gligorov J, Vanlemmens L, Trillet-Lenoir V, Arnould L, Coudert B.

Ann Oncol. 2011 Feb;22(2):321-8. Epub 2010 Aug 6.

PMID:20693300

 

Aromatase inhibition in male breast cancer patients: biological and clinical implications.

Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A.

Ann Oncol. 2010 Jun;21(6):1243-5. Epub 2009 Oct 27.

PMID:19861576

 

Prognostic role of pregnancy occurring before or after treatment of early breast cancer patients aged <35 years: a GET(N)A Working Group analysis.

Largillier R, Savignoni A, Gligorov J, Chollet P, Guilhaume MN, Spielmann M, Luporsi E, Asselain B, Coudert B, Namer M; GET(N)A Group.

Cancer. 2009 Nov 15;115(22):5155-65.

PMID:19691088

 

Docetaxel and pegylated liposomal doxorubicin combination as first-line therapy for metastatic breast cancer patients: results of the phase II GINECO trial CAPYTTOLE.

de la Fouchardière C, Largillier R, Goubely Y, Hardy-Bessard AC, Slama B, Cretin J, Orfeuvre H, Paraiso D, Bachelot T, Pujade-Lauraine E.

Ann Oncol. 2009 Dec;20(12):1959-63. Epub 2009 Jun 25.

PMID:19556321

 

Women’s perceptions and experience of adjuvant tamoxifen therapy account for their adherence: breast cancer patients’ point of view.

Pellegrini I, Sarradon-Eck A, Soussan PB, Lacour AC, Largillier R, Tallet A, Tarpin C, Julian-Reynier C.

Psychooncology. 2010 May;19(5):472-9.

PMID:19507263

 

A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.

Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi MC, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E.

Clin Cancer Res. 2009 May 15;15(10):3633-9. Epub 2009 Apr 28.

PMID:19401344

 

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial.

Kurtz JE, Hardy-Bessard AC, Deslandres M, Lavau-Denes S, Largillier R, Roemer-Becuwe C, Weber B, Guillemet C, Paraiso D, Pujade-Lauraine E.

Gynecol Oncol. 2009 Apr;113(1):16-20. Epub 2009 Feb 15.

PMID:19232434

 

Prognostic factors in 1,038 women with metastatic breast cancer.

Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, Courdi A, Hannoun-Levi JM, Ettore F, Birtwisle-Peyrottes I, Balu-Maestro C, Marcy PY, Raoust I, Lallement M, Chamorey E.

Ann Oncol. 2008 Dec;19(12):2012-9. Epub 2008 Jul 17.

PMID:18641006

 

Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.

Largillier R, Valenza B, Ferrero JM, Novo C, Creisson A, Lesbats G, Mari V, Hebert C, Chamorey E.

Oncology. 2007;73(3-4):177-84. Epub 2008 Apr 16.

PMID:18418010

 

Outcome and prognostic factors in breast sarcoma: a multicenter study from the rare cancer network.

Bousquet G, Confavreux C, Magné N, de Lara CT, Poortmans P, Senkus E, de Lafontan B, Bolla M, Largillier R, Lagneau E, Kadish S, Lemanski C, Ozsahin M, Belkacémi Y.

Radiother Oncol. 2007 Dec;85(3):355-61. Epub 2007 Nov 26.

PMID:18023492

 

Early versus late local recurrences after conservative treatment of breast carcinoma: differences in primary tumor characteristics and patient outcome.

Courdi A, Largillier R, Ferrero JM, Lallement M, Raoust I, Ettore F, Peyrottes I, Chamorey E, Balu-Maestro C, Chapellier C.

Oncology. 2006;71(5-6):361-8. Epub 2007 Aug 26.

PMID:17785993

 

Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity.

Beauclair S, Formento P, Fischel JL, Lescaut W, Largillier R, Chamorey E, Hofman P, Ferrero JM, Pagès G, Milano G.

Ann Oncol. 2007 Aug;18(8):1335-41.

PMID:17693647

 

Assessment of care by breast cancer patients participating or not participating in a randomized controlled trial: a report with the Patients’ Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.

Julian-Reynier C, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C, Maraninchi D; Patients’ Committee for Clinical Trials of the Ligue Nationale Contre le Cancer.

J Clin Oncol. 2007 Jul 20;25(21):3038-44. Epub 2007 May 29.

PMID:17536083

 

Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial.

Coudert BP, Largillier R, Arnould L, Chollet P, Campone M, Coeffic D, Priou F, Gligorov J, Martin X, Trillet-Lenoir V, Weber B, Bleuse JP, Vasseur B, Serin D, Namer M.

J Clin Oncol. 2007 Jul 1;25(19):2678-84. Epub 2007 May 21. Erratum in: J Clin Oncol. 2007 Nov 1;25(31):5048.

PMID:17515572

 

Decision-making and breast cancer clinical trials: how experience challenges attitudes.

Mancini J, Genève J, Dalenc F, Genre D, Monnier A, Kerbrat P, Largillier R, Serin D, Rios M, Roché H, Jimenez M, Tarpin C; Patients’ Committee for Clinical Trials of the Ligue Nationale, Julian Reynier C.

Contemp Clin Trials. 2007 Nov;28(6):684-94. Epub 2007 Mar 12.

PMID:17434812

 

 

Interstitial brachytherapy as the sole treatment for tongue metastasis from breast carcinoma.

Hannoun-Levi JM, Largillier R, Dassonville O.

Rev Laryngol Otol Rhinol (Bord). 2006;127(3):191-2.

PMID:17007196

 

Pharmacogenetics of capecitabine in advanced breast cancer patients.

Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, Francoual M, Renée N, Ferrero JM, Foa C, Namer M, Lacarelle B, Milano G.

Clin Cancer Res. 2006 Sep 15;12(18):5496-502.

PMID:17000685

 

Home infusions of biphosphonate in cancer patients: a prospective study.

Italiano A, Ciais C, Chamorey E, Marcy PY, Largillier R, Ferrero JM, Thyss A.

J Chemother. 2006 Apr;18(2):217-20.

PMID:16736892

 

Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients.

Courdi A, Ortholan C, Hannoun-Lévi JM, Ferrero JM, Largillier R, Balu-Maestro C, Chapellier C, Ettore F, Birtwisle-Peyrottes I.

Radiother Oncol. 2006 May;79(2):156-61. Epub 2006 May 15.

PMID:16698099

 

Primary embryonal rhabdomyosarcoma of the breast in an adult female.

Italiano A, Largillier R, Peyrottes I, Hannoun-Levy JM, Lallement M, Thyss A.

Breast J. 2005 May-Jun;11(3):214. No abstract available.

PMID:15871711

 

Cardiac toxicity assessment in locally advanced breast cancer treated neoadjuvantly with doxorubicin/paclitaxel regimen.

Magné N, Largillier R, Marcy PY, Magné J, Namer M.

Support Care Cancer. 2005 Oct;13(10):819-25. Epub 2005 Mar 30.

PMID:15798914

 

Long-term results of adjuvant hypofractionated radiotherapy for breast cancer in elderly patients.

Ortholan C, Hannoun-Lévi JM, Ferrero JM, Largillier R, Courdi A.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):154-62.

PMID:15629606

 

 

TEISSIER Eric

 

Classic biphasic pulmonary blastoma: A case report and review of the literature.

Le Caer H, Teissier E, Barriere JR, Venissac N.

Crit Rev Oncol Hematol. 2018 May;125:48-50. doi: 10.1016/j.critrevonc.2018.02.009. Epub 2018 Mar 3. Review.

PMID:29650276

 

Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction.

Moureau-Zabotto L, Teissier E, Cowen D, Azria D, Ellis S, Resbeut M.

Gastroenterol Res Pract. 2015;2015:404203. doi: 10.1155/2015/404203. Epub 2015 Sep 10.

PMID: 26448741

 

A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).

Delbaldo C, Serin D, Mousseau M, Greget S, Audhuy B, Priou F, Berdah JF, Teissier E, Laplaige P, Zelek L, Quinaux E, Buyse M, Piedbois P; Association Européenne de Recherche en Oncologie (AERO).

Eur J Cancer. 2014 Jan;50(1):23-30. doi: 10.1016/j.ejca.2013.09.023. Epub 2013 Oct 29.

PMID:24183460

 

Management and clinical outcome of rectal cancer in patients ≥ 80 years treated in southern France (PACA region) between 2006 and 2008.

Moureau-Zabotto L, Resbeut M, Gal J, Mineur L, Teissier E, Hebuterne X, Muyldermans P, Francois E, Chamorey E, Gerard JP.

J Surg Oncol. 2013 Dec;108(7):450-6. doi: 10.1002/jso.23428. Epub 2013 Sep 20.

PMID: 24115027

 

Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy.

Hennequin C, Bossard N, Servagi-Vernat S, Maingon P, Dubois JB, Datchary J, Carrie C, Roullet B, Suchaud JP, Teissier E, Lucardi A, Gerard JP, Belot A, Iwaz J, Ecochard R, Romestaing P.

Int J Radiat Oncol Biol Phys. 2013 Aug 1;86(5):860-6. doi: 10.1016/j.ijrobp.2013.03.021. Epub 2013 May 9.

PMID:23664327

 

Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study).

Moureau-Zabotto L, Ortholan C, Hannoun-Levi JM, Teissier E, Cowen D, Salem N, Lemanski C, Ellis S, Resbeut M.

Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e135-42. doi: 10.1016/j.ijrobp.2012.09.034. Epub 2012 Nov 27.

PMID:23195780

 

[Adenoid cystic carcinoma of the head and neck: a retrospective series of 169 cases].

Dubergé T, Bénézery K, Resbeut M, Azria D, Minsat M, Ellis S, Teissier E, Zaccariotto A, Champetier C, Cowen D.

Cancer Radiother. 2012 Jul-Aug;16(4):247-56. doi: 10.1016/j.canrad.2012.02.003. Epub 2012 May 29. French.

PMID:22652299

 

 

Anal Canal Cancer: Management of Inguinal Nodes and Benefit of Prophylactic Inguinal Irradiation (CORS-03 Study).

Ortholan C, Resbeut M, Hannoun-Levi JM, Teissier E, Gerard JP, Ronchin P, Zaccariotto A, Minsat M, Benezery K, François E, Salem N, Ellis S, Azria D, Champetier C, Gross E, Cowen D.

Int J Radiat Oncol Biol Phys. 2011 May 11. [Epub ahead of print]

PMID: 21570207

 

[Evaluation of immediate breast reconstruction and radiotherapy: factors associated with complications].

Gross E, Hannoun-Levi JM, Rouanet P, Houvenaeghel G, Teissier E, Ellis S, Resbeut M, Tallet A, Vaini Cowen V, Azria D, Cowen D.

Cancer Radiother. 2010 Dec;14(8):704-10. Epub 2010 Aug 2. French.

PMID: 20674442

 

High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study).

Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, Zaccariotto A, Bénézery K, François E, Salem N, Ellis S, Azria D, Gerard JP.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):712-20. Epub 2010 Jul 7.

PMID: 20619552

 

Immediate post-mastectomy breast reconstruction followed by radiotherapy: risk factors for complications.

Cowen D, Gross E, Rouannet P, Teissier E, Ellis S, Resbeut M, Tallet A, Cowen VV, Azria D, Hannoun-Levi JM.

Breast Cancer Res Treat. 2010 Jun;121(3):627-34. Epub 2010 Apr 28.

PMID: 20424909

 

Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.

François E, Berdah JF, Chamorey E, Lesbats G, Teissier E, Codoul JF, Badetti JL, Hébert C, Mari V.

Cancer Chemother Pharmacol. 2008 Nov;62(6):931-6. Epub 2008 Feb 14.

PMID:18273618

 

Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study.

Piedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, Teissier E, Berdah JF, Fabbro M, Valenza B, Herait P, Jehl V, Buyse M.

Ann Oncol. 2007 Jan;18(1):52-7. Epub 2006 Oct 17.

PMID: 17047001

 

 

RONCHIN Philippe

 

 

What is the optimal treatment for T1N0 anal squamous cell carcinoma? Analysis of current practices in the prospective French FFCD ANABASE cohort.

Bacci M, Quero L, Barbier E, Parrot L, Juguet F, Pommier P, Bazire L, Etienney I, Baba-Hamed N, Spindler L, François E, Ronchin P, Campo ERD, Lemanski C, Lièvre A, Siproudhis L, Abramowitz L, Lepage C, Vendrely V.

Dig Liver Dis. 2021 Apr 15:S1590-8658(21)00131-6. doi: 10.1016/j.dld.2021.03.015.

PMID: 33867291

 

MRI-Based Radiomics Input for Prediction of 2-Year Disease Recurrence in Anal Squamous Cell Carcinoma.

Giraud N, Saut O, Aparicio T, Ronchin P, Bazire LA, Barbier E, Lemanski C, Mirabel X, Etienne PL, Lièvre A, Cacheux W, Darut-Jouve A, De la Fouchardière C, Hocquelet A, Trillaud H, Charleux T, Breysacher G, Argo-Leignel D, Tessier A, Magné N, Ben Abdelghani M, Lepage C, Vendrely V.

Cancers (Basel). 2021 Jan 7;13(2):193. doi: 10.3390/cancers13020193.

PMID: 33430396 

 

Anal Canal Cancer: Management of Inguinal Nodes and Benefit of Prophylactic Inguinal Irradiation (CORS-03 Study).

Ortholan C, Resbeut M, Hannoun-Levi JM, Teissier E, Gerard JP, Ronchin P, Zaccariotto A, Minsat M, Benezery K, François E, Salem N, Ellis S, Azria D, Champetier C, Gross E, Cowen D.

Int J Radiat Oncol Biol Phys. 2011 May 11. [Epub ahead of print]

PMID:21570207

 

High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study).

Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, Zaccariotto A, Bénézery K, François E, Salem N, Ellis S, Azria D, Gerard JP.

Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):712-20. Epub 2010 Jul 7.

PMID:20619552

 

 

HOCH Benjamin

 

[We must respect the anti-SARS-CoV-2 vaccine schedule without delay in cancer patients under treatment].

Barrière J, Audigier-Valette C, Borchiellini D, Hoch B, Castelnau O, Francois E, Gastaud L, Skaf R, Berdah JF, Marie W, Lescaut W, Peyrade F, Cluzeau T, Cassuto O, Carles M.

Bull Cancer. 2021 Apr;108(4):341-342. doi: 10.1016/j.bulcan.2021.02.003. Epub 2021 Mar 5.

PMID: 33741139

 

Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey.

Barrière J, Gal J, Hoch B, Cassuto O, Leysalle A, Chamorey E, Borchiellini D.

Ann Oncol. 2021 May;32(5):673-674. doi: 10.1016/j.annonc.2021.01.066. Epub 2021 Jan 30.

PMID: 33529740 

 

« Real-world » evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy.

Niziers V, Boissier R, Borchiellini D, Deville JL, Khoury C, Durand M, Toledano H, Albert T, Branger N, Bandelier Q, Ouvrier MJ, Gabriel S, Hoch B, Gross E, Walz J, Brenot-Rossi I, Pignot G.

Urol Oncol. 2020 Jan;38(1):2.e1-2.e9. doi: 10.1016/j.urolonc.2019.07.017. Epub 2019 Aug 22.

PMID:31447087

 

mTOR inhibitors in advanced renal cell carcinomas: from biology to clinical practice.

Barthélémy P, Hoch B, Chevreau C, Joly F, Laguerre B, Lokiec F, Duclos B.

Crit Rev Oncol Hematol. 2013 Oct;88(1):42-56. doi: 10.1016/j.critrevonc.2013.02.006. Epub 2013 Mar 20.

PMID: 23523056

 

Renal cell carcinoma and a constitutional t(11;22)(q23;q11.2): case report and review of the potential link between the constitutional t(11;22) and cancer.

Doyen J, Carpentier X, Haudebourg J, Hoch B, Karmous-Benailly H, Ambrosetti D, Fabas T, Amiel J, Lambert JC, Pedeutour F.

Cancer Genet. 2012 Nov;205(11):603-7. doi: 10.1016/j.cancergen.2012.09.006. Epub 2012 Oct 30.

PMID: 23117075

 

New perspectives in the treatment of metastatic renal cell carcinoma.

Barrière J, Hoch B, Ferrero JM.

Crit Rev Oncol Hematol. 2011 Nov 16

PMID:22099727

 

A novel case of t(X;1)(p11.2;p34) in a renal cell carcinoma with TFE3 rearrangement and favorable outcome in a 57-year-old patient.

Haudebourg J, Hoch B, Fabas T, Burel-Vandenbos F, Carpentier X, Amiel J, Cardot-Leccia N, Michiels JF, Pedeutour F.

Cancer Genet Cytogenet. 2010 Jul 15;200(2):75-8.

PMID:20620589

 

Strength of molecular cytogenetic analyses for adjusting the diagnosis of renal cell carcinomas with both clear cells and papillary features: a study of three cases.

Haudebourg J, Hoch B, Fabas T, Cardot-Leccia N, Burel-Vandenbos F, Vieillefond A, Amiel J, Michiels JF, Pedeutour F.

Virchows Arch. 2010 Sep;457(3):397-404. Epub 2010 Jun 22.

PMID:20567845

 

BRACCINI Antoine

 

Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer.

Darlix A, Griguolo G, Thezenas S, Kantelhardt E, Thomssen C, Dieci MV, Miglietta F, Conte P, Braccini AL, Ferrero JM, Bailleux C, Jacot W, Guarneri V.

J Neurooncol. 2018 Feb 27. doi: 10.1007/s11060-018-2805-9.

PMID: 29488184

 

External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience.

Griguolo G, Jacot W, Kantelhardt E, Dieci MV, Bourgier C, Thomssen C, Bailleux C, Miglietta F, Braccini AL, Conte P, Ferrero JM, Guarneri V, Darlix A.

Breast. 2018 Feb;37:36-41. doi: 10.1016/j.breast.2017.10.006. Epub 2017 Oct 23.

PMID:29073498

 

Evaluation of reproducibility of tumor repositioning during multiple breathing cycles for liver stereotactic body radiotherapy treatment.

Bedos L, Riou O, Aillères N, Braccini A, Molinier J, Moscardo CL, Azria D, Fenoglietto P.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):132-140. doi: 10.1016/j.rpor.2016.07.007. Epub 2016 Nov 12.

PMID:28490984

 

Serum NSE, MMP-9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thézenas S, Jacot W.

Int J Cancer. 2016 Nov 15;139(10):2299-311. doi: 10.1002/ijc.30290.

PMID: 27464303

 

Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients.

Darlix A, Lamy PJ, Lopez-Crapez E, Braccini AL, Firmin N, Romieu G, Thezenas S, Jacot W.

BMC Cancer. 2016 Jul 7;16:428. doi: 10.1186/s12885-016-2448-1.

PMID: 27387327

 

Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.

Trédan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barrière J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthélémy P.

Target Oncol. 2015 Jun;10(2):189-98. doi: 10.1007/s11523-014-0334-9. Epub 2014 Sep 5. Review.

PMID:25185646

 

Radioanatomy of Rhinopharyngeal carcinoma

Braccini AL, Haberer-Guillerm S, Azria D, Garrel R, Pierre G , Auge Y , Boisselier P. Cancer Radiother. 2013. Accepted for publication

 

Prognostic factors of brain metastases from breast cancer: impact of targeted therapies.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferrero JM, Jacot W.

Breast. 2013 Oct;22(5):993-8

 

Comparative performances of prognostic indexes for breast cancer patients presenting with brain metastases.

Braccini AL, Azria D, Thezenas S, Romieu G, Ferreri JM, Jacot W.

BMC Cancer. 2013 Feb 8;13:70

 

4e IMPAKT Breast Cancer Conference, Métabolisme, voies de signalisation et cancers du sein, Cancers du sein triple-négatifs, pistes thérapeutiques, Biomarqueurs et biologie des cancers du sein, Perspectives.

  1. Lacroix-Triki, C. Villanueva, A.L. Braccini, F.C. Bidard, J. Barrière, O. Mir, O. Trédan, F. Dalenc, P. Barthélémy. Supplément Lettre du cancérologue septembre 2012.

 

How to treat brain metastasis in 2012?].

Braccini AL, Azria D, Mazeron JJ, Mornex F, Jacot W, Metellus P, Tallet A.

Cancer Radiother. 2012 Jul-Aug;16(4):309-14

 

Long term survival of an atlas osteosarcoma treated by surgery, chemotherapy and robotic stereotactic radiotherapy: a case report

Braccini AL, Bondiau PY, Litrico S, Burel-Vandenbos F, Thyss A.

Radiother Oncol. 2010 Dec;97(3):608-9. Epub 2010 Nov 11.

 

Paramètres biologiques de réponse tardive des tissus sains aux rayonnements ionisants

  1. Braccini, M. Ozsahin and D. Azria

Oncologie, 2010, Volume 12, Number 7, Pages 403-408

 

Focus sur la place des chimiothérapies et des thérapies ciblées dans le traitement des cancers colorectaux métastatiques en 2010

http://www.francecancer.net

 

LENGLET Alexis

 

Higher Anti-Tumor Efficacy of the Dual HER3-EGFR Antibody MEHD7945a Combined with Ionizing Irradiation in Cervical Cancer Cells.

Bourillon L, Demontoy S, Lenglet A, Zampieri A, Fraisse J, Jarlier M, Boissière-Michot F, Perrochia H, Rathat G, Garambois V, Bonnefoy N, Michaud HA, Chardès T, Tosi D, Pèlegrin A, Azria D, Larbouret C, Bourgier C.

Int J Radiat Oncol Biol Phys. 2020 Apr 1;106(5):1039-1051. doi: 10.1016/j.ijrobp.2019.12.020. Epub 2020 Jan 17.

PMID: 31959545

 

Long-term follow-up experience in anal canal cancer treated with Intensity-Modulated Radiation Therapy: Clinical outcomes, patterns of relapse and predictors of failure.

de Meric de Bellefon M, Lemanski C, Castan F, Samalin E, Mazard T, Lenglet A, Demontoy S, Riou O, Llacer-Moscardo C, Fenoglietto P, Aillères N, Thezenas S, Debrigode C, Vieillot S, Gourgou S, Azria D.

Radiother Oncol. 2020 Mar;144:141-147. doi: 10.1016/j.radonc.2019.11.016. Epub 2019 Dec 3.

PMID: 31809980

 

Risk-adapted stereotactic ablative radiotherapy for central and ultra-central lung tumours.

Lenglet A, Campeau MP, Mathieu D, Bahig H, Lambert L, Vu T, Roberge D, Bilodeau L, Filion E.

Radiother Oncol. 2019 May;134:178-184. doi: 10.1016/j.radonc.2019.01.035. Epub 2019 Feb 18.

PMID: 31005213

 

Central3D: A Computer Tool to Help Clinicians Differentiate Central and Peripheral Lung Tumors.

Mathieu D, Daoust VC, Campeau MP, Filion É, Bilodeau L, Bahig H, Roberge D, Lenglet A, Bedwani S.

Pract Radiat Oncol. 2019 Jan;9(1):e98-e102. doi: 10.1016/j.prro.2018.07.002. Epub 2018 Jul 18.

PMID: 30031220

 

SBRT planning for liver metastases: A focus on immobilization, motion management and planning imaging techniques.

Riou O, Llacer Moscardo C, Fenoglietto P, Deshayes E, Tetreau R, Molinier J, Lenglet A, Assenat E, Ychou M, Guiu B, Aillères N, Bedos L, Azria D.

Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):103-110. doi: 10.1016/j.rpor.2017.02.006. Epub 2017 Apr 6.

PMID: 28490980 

 

 

FALK Alexander

 

« Prolonged Efficacy of Pembrolizumab in a Patient Presenting a Multi-Treated Metastatic Hepatocholangiocarcinoma »

Saint, Angélique, Maxime Benchetrit, Sébastien Novellas, Denis Ouzan, Alexander Tuan Falk, Axel Leysalle, et Jérome Barriere.. Therapeutic Advances in Gastroenterology 13 (2020): 1756284820935189. https://doi.org/10.1177/1756284820935189.

 

« Mitomycin and 5-Fluorouracil for Second-Line Treatment of Metastatic Squamous Cell Carcinomas of the Anal Canal ».

Saint, Angélique, Ludovic Evesque, Alexander T. Falk, Gérard Cavaglione, Lucile Montagne, Karen Benezery, et Eric Francois. Cancer Medicine 8, no 16 (novembre 2019): 6853‑59. https://doi.org/10.1002/cam4.2558.

 

« GEC-ESTRO APBI Classification as a Decision-Making Tool for the Management of 2nd Ipsilateral Breast Tumor Event ».

Montagne, Lucile, Jocelyn Gal, Marie-Eve Chand, Renaud Schiappa, Alexander T. Falk, Rémy Kinj, Mathieu Gauthier, et Jean-Michel Hannoun-Levi. Breast Cancer Research and Treatment 176, no 1 (juillet 2019): 149‑57. https://doi.org/10.1007/s10549-019-05221-z.

 

     « Efficacy and Tolerance of Thoracic Radiotherapy in the Oldest Old Patients: A Case Series ».

Mery, Benoite, Chloe Rancoule, Avi Assouline, Lounis Aissou, Alexander T. Falk, Pierre Auberdiac, Alexis Vallard, Cyrus Chargari, et Nicolas Magné. Indian Journal of Cancer 56, no 2 (juin 2019): 163‑66. https://doi.org/10.4103/ijc.IJC_346_18.

 

. « Intensity-Modulated Radiation Therapy of Anal Squamous Cell Carcinoma: Relationship between Delineation Quality and Regional Recurrence ».

Rouard, Nathalie, Didier Peiffert, Emmanuel Rio, Marc-André Mahé, Gregory Delpon, Vincent Marchesi, Alexander T. Falk, Julia Salleron, et Anne-Agathe Serre Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology 131 (février 2019): 93‑100. https://doi.org/10.1016/j.radonc.2018.10.021.

 

« Prostate-Specific Antigen Bounce in Patients Treated before 60 Years Old by Iodine 125 Brachytherapy for Prostate Cancer Is Frequent and Not a Prognostic Factor ».

Charret, J., A. S. Baumann, P. Eschwege, J. L. Moreau, V. Bernier, A. T. Falk, J. Salleron, et D. Peiffert. Brachytherapy 17, no 6 (décembre 2018): 888‑94. https://doi.org/10.1016/j.brachy.2018.07.011.

       

     « Efficacy and Tolerance of High-Dose-Rate Brachytherapy Boost after External Radiotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal ».

Bertin, Emilien, Karen Benezery, Daniel Lam Cham Kee, Eric François, Ludovic Evesque, Mathieu Gautier, Jean-Pierre Gerard, Jean-Michel Hannoun-Levi, et Alexander T. Falk. Journal of Contemporary Brachytherapy 10, no 6 (décembre 2018): 522‑31. https://doi.org/10.5114/jcb.2018.81025.

 

 

« Brachytherapy versus External Beam Radiotherapy Boost for Prostate Cancer: Systematic Review with Meta-Analysis of Randomized Trials »

Kee, Daniel Lam Cham, Jocelyn Gal, Alexander T. Falk, Renaud Schiappa, Marie-Eve Chand, Mathieu Gautier, Jérôme Doyen, et Jean-Michel Hannoun-Levi.. Cancer Treatment Reviews 70 (novembre 2018): 265‑71. https://doi.org/10.1016/j.ctrv.2018.10.004.

 

« Effect of Mutant Variants of the KRAS Gene on PD-L1 Expression and on the Immune Microenvironment and Association with Clinical Outcome in Lung Adenocarcinoma Patients ».

Falk, Alexander T., Nathalie Yazbeck, Nicolas Guibert, Emmanuel Chamorey, Agnès Paquet, Lydia Ribeyre, Coraline Bence, et al. Lung Cancer (Amsterdam, Netherlands) 121 (juillet 2018): 70‑75. https://doi.org/10.1016/j.lungcan.2018.05.009.

 

« Pain after Tonsillectomy: Effectiveness of Current Guidelines? »

Walrave, Y., C. Maschi, S. Bailleux, A. T. Falk, C. Hayem, M. Carles, et F. De la Brière. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 275, no 1 (janvier 2018): 281‑86. https://doi.org/10.1007/s00405-017-4788-0.

 

« A Retrospective Survey of the Last 3 Months of Life in Patients Carrying Glioblastoma: Clinical Treatments and Profiles ».

Rivoirard, Romain, Alexis Vallard, Claire Boutet, Alexander Tuan Falk, Clemence Garin, Anissa Adjabi, Delphine Hoarau, et al. Molecular and Clinical Oncology 8, no 1 (janvier 2018): 115‑20. https://doi.org/10.3892/mco.2017.1479.

 

« High-Dose-Rate Brachytherapy Boost for Prostate Cancer: Comparison of Three Different Fractionation Schemes »

Falk, Alexander T., Sylvain Demontoy, Emmanuel Chamorey, Marie-Eve Chand, Mathieu Gautier, David Azria, Sara Zaki, Daniel Chevallier, Daniel Lam Cham Kee, et Jean-Michel Hannoun-Lévi.. Brachytherapy 16, no 5 (octobre 2017): 993‑99. https://doi.org/10.1016/j.brachy.2017.06.013.

 

« NGS Analysis on Tumor Tissue and CfDNA for Genotype-Directed Therapy in Metastatic NSCLC Patients. Between Hope and Hype? »

Falk, Alexander T., Simon Heeke, Véronique Hofman, Virginie Lespinet, Camille Ribeyre, Olivier Bordone, Michel Poudenx, et al. Expert Review of Anticancer Therapy 17, no 8 (août 2017): 681‑85. https://doi.org/10.1080/14737140.2017.1331736.

 

« Radiotherapy among Nonagenarians with Anal or Rectal Carcinoma: Should We Avoid or Adapt Treatment? »

Vallard, Alexis, Chloé Rancoule, Jean-Baptiste Guy, Avi Assouline, Alexander T. Falk, Pierre Auberdiac, Julien Langrand-Escure, Cyrus Chargari, et Nicolas Magné Chinese Journal of Cancer 36, no 1 (14 juillet 2017): 56. https://doi.org/10.1186/s40880-017-0224-5.

 

     « Radiotherapy for Elderly Patients and Cetuximab, a Monocentric Study ».

Falk, Alexander T., Christophe Hébert, Antoine Tran, Marie-Eve Chand, Axel Leysalle, Juliette Thariat, Olivier Dassonville, et al. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 274, no 2 (février 2017): 1061‑65. https://doi.org/10.1007/s00405-016-4336-3.

 

« PD-L1 Expression in Basaloid Squamous Cell Lung Carcinoma: Relationship to PD-1+ and CD8+ Tumor-Infiltrating T Cells and Outcome ».

Ilie, Marius, Alexander T. Falk, Catherine Butori, Emmanuel Chamorey, Christelle Bonnetaud, Elodie Long, Sandra Lassalle, et al. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 29, no 12 (décembre 2016): 1552‑64. https://doi.org/10.1038/modpathol.2016.149.

 

« Targeting Stem Cells by Radiation: From the Biological Angle to Clinical Aspects ».

Vallard, Alexis, Sophie Espenel, Jean-Baptiste Guy, Peng Diao, Yaoxiong Xia, Anis El Meddeb Hamrouni, Majed Ben Mrad, et al. World Journal of Stem Cells 8, no 8 (26 août 2016): 243‑50. https://doi.org/10.4252/wjsc.v8.i8.243.

 

« Brachytherapy and Fertility ».

Falk, Alexander Tuan, Cyrus Chargari, Jean-Michel Hannoun-Lévi, Caroline Adrados, Julie Antomarchi, Jean-Baptiste Guy, Renaud Mazeron, Christine Haie-Meder, et Nicolas Magné. Human Fertility (Cambridge, England) 19, no 2 (juin 2016): 85‑89. https://doi.org/10.1080/14647273.2016.1190466.

 

     « [Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study] ».

Cervetti, Louise, Alexis Vallard, Sylvestre Le Moulec, Sophie Espenel, Alexander Tuan Falk, Majed Ben Mrad, Jean-Baptiste Guy, et al. Bulletin Du Cancer 103, no 6 (juin 2016): 561‑70. https://doi.org/10.1016/j.bulcan.2016.03.008.

 

     « Radiotherapy for Gynecologic Cancer in Nonagenarian Patients: A Framework for New Paradigms ».

Méry, Benoîte, Sylvie Mengue Ndong, Jean-Baptiste Guy, Avi Assouline, Alexander T. Falk, Anaïs Valeille, Jane-Chloé Trone, Alexander T Falk et al. Chinese Journal of Cancer 35 (9 mai 2016): 43. https://doi.org/10.1186/s40880-016-0104-4.

 

     « Proton Beams in Cancer Treatments: Clinical Outcomes and Dosimetric Comparisons with Photon Therapy ».

Doyen, Jérôme, Alexander Tuan Falk, Vincent Floquet, Joël Hérault, et Jean-Michel Hannoun-Lévi. Cancer Treatment Reviews 43 (février 2016): 104‑12. https://doi.org/10.1016/j.ctrv.2015.12.007.

 

. « Concomitant Cervical and Transperineal Parametrial High-Dose-Rate Brachytherapy Boost for Locally Advanced Cervical Cancer ».

Bailleux, Caroline, Alexander Tuan Falk, Marie-Eve Chand-Fouche, Mathieu Gautier, Emmanuel Barranger, et Jean-Michel Hannoun-LeviJournal of Contemporary Brachytherapy 8, no 1 (février 2016): 23‑31. https://doi.org/10.5114/jcb.2016.57535.

 

« Intensity-Modulated Salvage Radiotherapy with Simultaneous Integrated Boost for Local Recurrence of Prostate Carcinoma: A Pilot Study on the Place of PET-Choline for Guiding Target Volume Delineation ».

Wahart, Aurélien, Jean-Baptiste Guy, Alexis Vallard, Benjamin Geissler, Majed Ben Mrad, Alexander T. Falk, Nathalie Prevot, et al. The British Journal of Radiology 89, no 1058 (2016): 20150579. https://doi.org/10.1259/bjr.20150579.

 

     « Chemotherapy Regimen in Nonagenarian Cancer Patients: A Bi-Institutional Experience ».

Rivoirard, Romain, Cyrus Chargari, Sharif Kullab, Jane-Chloé Trone, Julien Langrand-Escure, Guillaume Moriceau, Jean-Baptiste Guy, Alexander T Falk et al. Chemotherapy 61, no 2 (2016): 65‑71. https://doi.org/10.1159/000441018.

       

« Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study) ».

Rivoirard, Romain, Cyrus Chargari, Jean-Baptiste Guy, Christophe Nuti, Michel Peoc’h, Fabien Forest, Alexander Tuan Falk, et al. Chemotherapy 61, no 5 (2016): 269‑74. https://doi.org/10.1159/000443719.

 

« Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients »

Moriceau, Guillaume, Aline Guillot, Cécile Pacaut, Benoîte Méry, Alexander Tuan Falk, Jane-Chloé Trone, Olivier Collard, et al.. Chemotherapy 61, no 3 (2016): 127‑33. https://doi.org/10.1159/000441379.

 

« Dosimetric Study of Volumetric Arc Modulation with RapidArc and Intensity-Modulated Radiotherapy in Patients with Cervical Cancer and Comparison with 3-Dimensional Conformal Technique for Definitive Radiotherapy in Patients with Cervical Cancer ».

Guy, Jean-Baptiste, Alexander T. Falk, Pierre Auberdiac, Lysian Cartier, Alexis Vallard, Edouard Ollier, Jane-Chloé Trone, Moustapha Khodri, Cyrus Chargari, et Nicolas Magné. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists 41, no 1 (2016): 9‑14. https://doi.org/10.1016/j.meddos.2015.06.002.

 

« The Evolving Locally-Advanced Non-Small Cell Lung Cancer Landscape: Building on Past Evidence and Experience »

Méry, Benoite, Jean-Baptiste Guy, Aurélie Swalduz, Alexis Vallard, Cyril Guibert, Hweej Almokhles, Majed Ben Mrad, Alexander T Falk et al.. Critical Reviews in Oncology/Hematology 96, no 2 (novembre 2015): 319‑27. https://doi.org/10.1016/j.critrevonc.2015.05.020.

 

 

 

« Integrating Genomics in Head and Neck Cancer Treatment: Promises and Pitfalls ».

Thariat, Juliette, Stéphane Vignot, Ariane Lapierre, Alexander T. Falk, Joel Guigay, Ellen Van Obberghen-Schilling, et Gerard Milano. Critical Reviews in Oncology/Hematology 95, no 3 (septembre 2015): 397‑406. https://doi.org/10.1016/j.critrevonc.2015.03.005.

 

« Long-Term Results of a Survey of Prolonged Adjuvant Treatment with Temozolomide in Patients with Glioblastoma (SV3 Study) ».

Rivoirard, R., A. T. Falk, C. Chargari, J.-B. Guy, B. Mery, C. Nuti, M. Peoc’h, et al. Clinical Oncology (Royal College of Radiologists (Great Britain)) 27, no 8 (août 2015): 486‑87. https://doi.org/10.1016/j.clon.2015.04.003.

 

« Treating Metastatic Sarcomas Locally: A Paradoxe, a Rationale, an Evidence? »

Olivier, Timothée, Daniel Pop, Amina Chouiter Djebaili, Alexander Tuan Falk, Antoine Iannessi, Esma Saada, Willy Nettekoven, et alCritical Reviews in Oncology/Hematology 95, no 1 (juillet 2015): 62‑77. https://doi.org/10.1016/j.critrevonc.2015.01.004.

 

« Hypofractionated Radiation Therapy for Treatment of Bladder Carcinoma in Patients Aged 90 Years and More: A New Paradigm to Be Explored? »

Méry, Benoîte, Alexander T. Falk, Avi Assouline, Jane-Chloé Trone, Jean-Baptiste Guy, Romain Rivoirard, Pierre Auberdiac, et al. International Urology and Nephrology 47, no 7 (juillet 2015): 1129‑34. https://doi.org/10.1007/s11255-015-0999-8.

 

« Metastatic Ablation for Sarcomas: Methodological and Ethical Dilemmas for Prospective Studies ».

Falk, A. T., A. Thyss, et J. Thariat. Clinical Oncology (Royal College of Radiologists (Great Britain)) 27, no 7 (juillet 2015): 429‑30. https://doi.org/10.1016/j.clon.2015.03.009.

 

« Skin Cancers in Nonagenarian Patients: Special Focus on Radiotherapy ».

Trone, J.-C., S. Mengue Ndong, A. T. Falk, P. Annede, R. Rivoirard, J.-B. Guy, J. Langrand-Escure, et al. Clinical Oncology (Royal College of Radiologists (Great Britain)) 27, no 6 (juin 2015): 371. https://doi.org/10.1016/j.clon.2015.01.031.

 

« Bevacizumab: A Dose Review ».

Falk, Alexander T., Jérôme Barrière, Eric François, et Philippe Follana. Critical Reviews in Oncology/Hematology 94, no 3 (juin 2015): 311‑22. https://doi.org/10.1016/j.critrevonc.2015.01.012.

 

« Impact of Fluconazole versus Posaconazole Prophylaxis on the Incidence of Fungal Infections in Patients Receiving Induction Chemotherapy for Acute Myeloid Leukemia »

Devanlay, Camille, Emmanuelle Tavernier-Tardy, Aurélie Bourmaud, Alexander Tuan Falk, Hélène Raberin, Sandrine Menguy, Denis Guyotat, Nicolas Magné, et Jérôme Cornillon. Biomedical Journal 38, no 3 (juin 2015): 235‑43. https://doi.org/10.4103/2319-4170.143491.

 

« Second Salvage Treatment for Local Recurrence of Prostate Cancer Using High-Dose-Rate Brachytherapy: A Case Report ».

Claren, Audrey, Mathieu Gautier, Julien Feuillade, Alexander Tuan Falk, et Jean-Michel Hannoun Levi. Journal of Contemporary Brachytherapy 7, no 3 (juin 2015): 244‑47. https://doi.org/10.5114/jcb.2015.51852.

 

« Safety of Spinal Radiotherapy in Metastatic Cancer Patients Receiving Bevacizumab Therapy: A Bi-Institutional Case Series ».

Mbagui, Rodrigue, Julien Langrand-Escure, Pierre Annede, Benoite Mery, Bernard Ceccaldi, Jean-Baptiste Guy, Alexander T. Falk, et al. Anti-Cancer Drugs 26, no 4 (avril 2015): 443‑47. https://doi.org/10.1097/CAD.0000000000000204.

 

« Radiotherapy for Head and Neck Cancer in Nonagenarian Patients: A Possible Cornerstone? »

Rivoirard, Romain, Coralie Moncharmont, Avi Assouline, Pierre Auberdiac, Benoite Mery, Alexander Tuan Falk, Pierre Annède, et al. European Archives of Oto-Rhino-Laryngology: Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): Affiliated with the German Society for Oto-Rhino-Laryngology – Head and Neck Surgery 272, no 3 (mars 2015): 719‑25. https://doi.org/10.1007/s00405-014-3017-3.

« Thromboembolic Events Following Brachytherapy: Case Reports ».

Guy, Jean-Baptiste, Alexander Tuan Falk, Cyrus Chargari, Laurent Bertoletti, et Nicolas Magné. Journal of Contemporary Brachytherapy 7, no 1 (février 2015): 76‑78. https://doi.org/10.5114/jcb.2015.48580.

 

« Effect on Survival of Local Ablative Treatment of Metastases from Sarcomas: A Study of the French Sarcoma Group »

Falk, A. T., L. Moureau-Zabotto, M. Ouali, N. Penel, A. Italiano, J.-O. Bay, T. Olivier, et al.. Clinical Oncology (Royal College of Radiologists (Great Britain)) 27, no 1 (janvier 2015): 48‑55. https://doi.org/10.1016/j.clon.2014.09.010.

 

« Correlation of Physical Activities and Breast Cancer Characteristics: A Prospective Analysis with Special Focus on Triple Negative Breast Cancer ».

Vallard, Alexis, Alexander Tuan Falk, Pascale Antoine, Jean-Baptiste Guy, Jean-Baptiste Guichard, Sophie Espenel, Julien Langrand-Escure, et al. Oncology 89, no 5 (2015): 262‑68. https://doi.org/10.1159/000437229.

 

« OSNA (One-Step Nucleic Acid Amplification) Sentinel Lymph Node Intraoperative Molecular Analysis in Breast Cancer: A Cost-Benefit Analysis ».

Raia-Barjat, Tiphaine, Béatrice Trombert, Abir Khaddage, Catherine Douchet, Pierre Seffert, Michel Peoc’h, Alexander Tuan Falk, Nicolas Magné, et Céline Chauleur. Medical Oncology (Northwood, London, England) 31, no 12 (décembre 2014): 322. https://doi.org/10.1007/s12032-014-0322-z.

 

« Interstitial High-Dose Rate Brachytherapy as Boost for Anal Canal Cancer ».

Falk, Alexander Tuan, Audrey Claren, Karen Benezery, Eric François, Mathieu Gautier, Jean-Pierre Gerard, et Jean-Michel Hannoun-LeviRadiation Oncology (London, England) 9 (6 novembre 2014): 240. https://doi.org/10.1186/s13014-014-0240-4.

 

« Radiation-Enhanced Cell Migration/Invasion Process: A Review ».

Moncharmont, Coralie, Antonin Levy, Jean-Baptiste Guy, Alexander T. Falk, Matthieu Guilbert, Jane-Chloé Trone, Gersende Alphonse, et al. Critical Reviews in Oncology/Hematology 92, no 2 (novembre 2014): 133‑42. https://doi.org/10.1016/j.critrevonc.2014.05.006.

 

« [New external radiotherapy technologies for breast cancer] ».

Falk, A. T., P. Fenoglietto, D. Azria, et C. Bourgier. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique 18, no 5‑6 (octobre 2014): 480‑85. https://doi.org/10.1016/j.canrad.2014.06.018.

 

« [Cervical lymph nodes: surgeon’s point of view] ».

Dassonville, O., A.-T. Falk, et G. Poissonnet

Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique 18, no 5‑6 (octobre 2014): 549‑52. https://doi.org/10.1016/j.canrad.2014.06.020.

 

« [Radiation-induces increased tumor cell aggressiveness of tumors of the glioblastomas?] ».

Falk, Alexander T., Coralie Moncharmont, Matthieu Guilbert, Jean-Baptiste Guy, Gersende Alphonse, Jane-Chloé Trone, Romain Rivoirard, et alBulletin Du Cancer 101, no 9 (septembre 2014): 876‑80. https://doi.org/10.1684/bdc.2014.1946.

 

« High-Dose Rate Brachytherapy in Localized Penile Cancer: Short-Term Clinical Outcome Analysis ».

Rouscoff, Yohann, Alexander Tuan Falk, Matthieu Durand, Jocelyn Gal, Marie-Eve Chand, Mathieu Gautier, Alexandre Marsaud, Daniel Chevallier, Jean Amiel, et Jean-Michel Hannoun-Levi. Radiation Oncology (London, England) 9 (19 juin 2014): 142. https://doi.org/10.1186/1748-717X-9-142.

 

« Portrait, Treatment Choices and Management of Breast Cancer in Nonagenarians: An Ongoing Challenge ».

Méry, Benoite, Avi Assouline, Romain Rivoirard, Claire Bosacki, Pierre Auberdiac, Alexander T. Falk, Jane-Chloé Trone, et al. Breast (Edinburgh, Scotland) 23, no 3 (juin 2014): 221‑25. https://doi.org/10.1016/j.breast.2014.03.006.

 

« [Primary digestive melanomas: is there any consensus?] ».

Eddekkaoui, Houda, Jean-Baptiste Guy, Alexander T. Falk, Rima Lahmar, Jane-Chloé Trone, Mohun R. K. Bahadoor, Sharif Kullab, et al. Bulletin Du Cancer 101, no 6 (juin 2014): 637‑40. https://doi.org/10.1684/bdc.2014.1948.

 

« Results of Age-Dependent Anal Canal Cancer Treatment: A Single Centre Retrospective Study ».

Claren, Audrey, Jerôme Doyen, Alexander T. Falk, Karen Benezery, Philippe Follana, Anne-Claire Frin, Jean-Michel Hannoun-Lévi, et al. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 46, no 5 (mai 2014): 460‑64. https://doi.org/10.1016/j.dld.2014.01.004.

 

« Feasibility of Radiation Therapy in Patients 90years of Age and Older: A French Multicentre Analysis ».

Chargari, Cyrus, Guillaume Moriceau, Pierre Auberdiac, Jean-Baptiste Guy, Avi Assouline, Fabien Tinquaut, Alexander Tuan Falk, et al. European Journal of Cancer (Oxford, England: 1990) 50, no 8 (mai 2014): 1490‑97. https://doi.org/10.1016/j.ejca.2014.02.012.

 

« Cardiotoxicity Research in Breast Cancer Patients: Past and Future ».

Chargari, Cyrus, Jean-Baptiste Guy, Alexander T. Falk, Elie D. Schouver, Jane-Chloé Trone, Coralie Moncharmont, Lionel Védrine, et Nicolas Magné. The American Journal of Cardiology 113, no 8 (15 avril 2014): 1447‑48. https://doi.org/10.1016/j.amjcard.2014.01.421.

 

« General Management of Nonagenarian Patients: A Review of the Literature ».

Rivoirard, Romain, Cyrus Chargari, Jane-Chloé Trone, Alexander Tuan Falk, Jean-Baptiste Guy, Houda Eddekaoui, Rima Lahmar, et al. Swiss Medical Weekly 144 (2014): w14059. https://doi.org/10.4414/smw.2014.14059.

 

« The Combination of 80 Years of Age and Metastatic Castration-Resistant Prostate Cancer Remain an Uphill Battle: A Case Report with Cabazitaxel as a Double-Edged Sword ».

Méry, Benoite, Jane-Chloé Trone, Guillaume Moriceau, Alexander Tuan Falk, Aline Guillot, Cécile Pacaut, Olivier Collard, et Nicolas Magné. Chemotherapy 60, no 5‑6 (2014): 300‑301. https://doi.org/10.1159/000377620.

 

« Epithelioid Hemangioendothelioma of the Spine Treated with RapidArc Volumetric-Modulated Radiotherapy ».

Guy, Jean-Baptiste, Jane-Chloé Trone, Cyrus Chargari, Alexander Tuan Falk, Mustapha Khodri, et Nicolas Magné. Medical Dosimetry: Official Journal of the American Association of Medical Dosimetrists 39, no 3 (2014): 242‑45. https://doi.org/10.1016/j.meddos.2014.03.002.

 

« Adenocarcinoma of the Lung with Miliary Brain and Pulmonary Metastases with Echinoderm Microtubule-Associated Protein like 4-Anaplastic Lymphoma Kinase Translocation Treated with Crizotinib: A Case Report ».

Falk, Alexander T., Michel Poudenx, Josiane Otto, Hannah Ghalloussi, et Jérôme Barrière. Lung Cancer (Amsterdam, Netherlands) 78, no 3 (décembre 2012): 282‑84. https://doi.org/10.1016/j.lungcan.2012.08.015.

 

Psychologie

Le suivi psychologique fait partie intégrante de la prise en charge globale des personnes touchées par le cancer. Ses conséquences psychologiques peuvent affecter l’estime de soi, sa relation avec les autres ou encore sa qualité de vie. Un soutien psychologique peut être bénéfique pour les patients ainsi que pour les proches et aidants. Le psychologue est là pour aider les patients à gérer leurs émotions et le stress induit par l’annonce du cancer, de mieux comprendre les effets physiques et psychologiques de la maladie, et de trouver des moyens de soutenir les proches. Le suivi psychologique est ouvert à tous ceux qui en ressentent le besoin.

Coiffure et prothèse capillaire

La perte de cheveux est un effet secondaire fréquent des traitements de chimiothérapie. Cependant, il existe des options pour aider les patients à retrouver leur confiance en eux et à améliorer leur qualité de vie. La socio-coiffeuse et la prothésiste capillaire peuvent vous accompagner dans cette étape difficile pour mieux vivre les effets secondaires induits par certaines chimiothérapies. Différentes approches, complémentaires, sont à votre disposition :

• La socio-coiffeuse est formée pour accompagner et apporter aux patients du bien-être, réconfort et des solutions pour une meilleure estime de soi : coupe de vos cheveux, couleur, soins spécifiques.

• La prothésiste capillaire médicale propose des modèles de prothèse capillaire (perruques) fabriquées à partir de fibres synthétiques ou naturelles de haute qualité. Elles sont conçues pour être confortables à porter et faciles à entretenir. Celles-ci peuvent être adaptées à la forme de la tête et à la couleur naturelle des cheveux. Une prise en charge est prévue par les caisses d’assurance maladie en fonction de sa composition.

• Des foulards, bandeaux, bonnets peuvent également être proposés.

Ostéopathie

L'ostéopathie est une approche thérapeutique qui peut aider les patients à gérer les effets secondaires de la maladie et des traitements. Elle traite les douleurs et les raideurs articulaires, en soulageant la tension musculaire et en améliorant la circulation sanguine. Elle peut également aider à réduire la fatigue et la douleur induites par la maladie. L'ostéopathie est adaptée à chaque individu en fonction de ses besoins et de ses capacités. Les consultations se font avec un ostéopathe qualifié qui connaît bien les problématiques liées à la cancérologie. Ainsi, il pourra élaborer un plan de traitement adapté. L'ostéopathie peut être pratiquée à tout stade de la maladie avec l’accord de votre Oncologue.

Réflexologie plantaire

La réflexologie est une méthode de médecine douce et naturelle qui consiste à exercer des points de pression au niveau des zones réflexes des pieds.

Elle contribue à atténuer le stress en procurant une relaxation générale, revitaliser le corps tout en renforçant les défenses immunitaires, améliorer la circulation sanguine, faciliter les fonctions d'élimination du corps, aider à traiter une grande quantité de maux bénins du quotidien et aider le corps à retrouver son équilibre.

La réflexologie est une technique naturelle ancestrale qui produit ses bienfaits depuis plus de 5000 ans.

Le pied est la représentation miniaturisée du corps humain. A chaque zone réflexe correspond un organe, une glande ou une partie du corps. Un toucher spécifique sur ces zones permet de rétablir l'équilibre dans les parties du corps correspondantes. Elle a pour but de stimuler les mécanismes d’auto-guérison du corps pour rétablir et maintenir l’homéostasie (équilibre naturel du corps).

La réflexologie plantaire considère l’individu dans sa globalité. Elle accompagne un traitement, prévient et entretient une bonne santé.

CONTRE - INDICATIONS
Le réflexologue ne peut pas intervenir en cas de :
- Thrombophlébite
- Fracture et entorse du pied
- Grossesse : durant les 3 premiers mois

Soins socio-esthétiques

Les soins socio-esthétiques favorisent le processus de guérison par la communication, le mieux-être et par une prise en charge globale des personnes atteintes du cancer. Ils peuvent aider à gérer les effets secondaires physiques et psychologiques de la maladie et des traitements. Ils peuvent inclure des services tels que les massages, les soins de la peau, et les maquillages. Ces services peuvent aider les patients à se sentir mieux dans leur corps et à améliorer leur estime de soi. Ces soins permettent à tous les patients qui le souhaitent, de prendre un temps pour soi, pour se détendre et pour accepter la maladie dans la douceur. Ces soins peuvent également aider à gérer les effets secondaires de la maladie tels que la fatigue, la douleur, le stress.

Activité Physique Adaptée

Les activités physiques adaptées sont un moyen efficace de gérer les effets secondaires du traitement du cancer et de renforcer le bien-être physique et mental. Elles peuvent être pratiquées à tout stade de la maladie, et sont adaptées aux besoins et aux capacités de chaque individu. Ces activités peuvent aider à améliorer la force musculaire, l'endurance, la flexibilité et la qualité de vie. Elles peuvent également contribuer à réduire la fatigue, l'anxiété et la dépression, et à améliorer le sommeil.
L’objectif est de développer un plan d'exercice sûr et efficace qui conviendra à vos besoins. L'activité physique adaptée est un excellent moyen de prendre soin de soi pendant et après le traitement du cancer. Les APA contribuent à lutter contre la récidive et améliorent la qualité de vie des patients. C'est un moyen de se sentir plus fort, plus en contrôle de son corps et de son esprit.

L’activité physique est pratiquée en salle et/ou en plein air.

Une participation financière est demandée : 15€/mois pour 1 cours hebdomadaire et 21€/ mois pour 2 cours hebdomadaires

Art-thérapie

L'art-thérapie est une approche thérapeutique qui peut aider les patients atteints de cancer à gérer leur anxiété et leur stress, en rendant visible leurs émotions physiques et psychiques à travers la créativité et les images.

Elle permet de rendre visible et de donner une voix à des émotions et des expériences souvent indescriptibles en utilisant l’expression artistique. Elle permet de se découvrir, de faire ressortir les traumatismes passés ou présents, de stimuler la créativité pour remplacer ses images intérieurs négatives par des images positives de paix et de sérénité.

L’art-thérapie peut aider à accroître la compréhension de soi, de la maladie et de son traitement, en favorisant une meilleure acceptation de la maladie.

Dermopigmentation médicale

La dermopigmentation médicale est une technique innovante qui peut aider les patients atteints d’un cancer à retrouver leur confiance en eux et à mieux vivre avec les effets secondaires des traitements de la chimiothérapie : alopécie sourcilière.

En utilisant des pigments spéciaux, les professionnels de la dermopigmentation médicale peuvent aider les patients à masquer la perte des sourcils causée par la chimiothérapie. Le dermographe peut aider les patients à retrouver leur apparence initiale et à se sentir mieux dans leur peau.

Le tatouage médical est réalisé par des professionnels de santé formés et qualifiés qui utilisent des pigments de qualité supérieure pour reproduire les couleurs et les nuances de la peau. Cela garantit des résultats visiblement naturels, qui s’estomperont pour laisser la place à la repousse des sourcils naturels.

Diététique nutrition

La diététique et la nutrition sont des aspects importants de la prise en charge globale des personnes atteintes de cancer. Une alimentation adaptée peut aider à gérer les effets physiques et psychologiques de la maladie et des traitements. Une diététicienne-nutritionniste qualifiée aide les patients à élaborer un plan alimentaire adapté à leurs besoins individuels en tenant compte de leur état de santé, de leur traitement et de leurs préférences alimentaires. Elle peut également aider à gérer les effets secondaires de la maladie tels que la perte de poids, la fatigue et les nausées. Une alimentation équilibrée et riche en nutriments peut aider à maintenir une bonne santé globale et à réduire le risque de complications liées à la maladie.

Deux types de RDV sont pris en charge par ISIS :
- 1 à 2 entretiens individuels de 30' pour répondre aux interrogations et préoccupations du quotidien de manière générale.
- 1 à 2 consultations afin de déterminer un plan personnalisé de nutrition après un bilan approfondi.

Yoga

La pratique régulière du yoga peut aider à améliorer la qualité de vie des patients en cancérologie en réduisant les effets secondaires de la maladie et des traitements, en améliorant la force physique et en augmentant la capacité à gérer les émotions.

Les postures de yoga peuvent aider à améliorer la flexibilité, la force musculaire, la respiration et la circulation sanguine. Les techniques de relaxation telles que la méditation et la respiration peuvent aider à réduire l'anxiété et la dépression. Les cours de yoga adaptés pour les personnes atteintes de cancer sont dispensés par des enseignants qualifiés qui connaissent les effets secondaires de la maladie et peuvent adapter les postures et les exercices en fonction de chaque patient.

Santé sexuelle

La santé sexuelle est un aspect important de la prise en charge globale des personnes atteintes de cancer. Les patients peuvent être touchés par les effets physiques et psychologiques de la maladie et des traitements, qui peuvent avoir un impact sur leur vie sexuelle.
Quel que soit le cancer et quel que soit le stade de la maladie et de son traitement, la vie intime et sexuelle peut être perturbée. Prendre en compte les troubles sexuels fait partie intégrante de la démarche médicale afin de soigner un individu et pas seulement un organe malade.
Il est important que les patients soient informés des effets possibles de la maladie et des traitements sur leur vie sexuelle, et de disposer de ressources pour les aider à gérer ces effets.
La thérapie sexuelle et les médicaments peuvent être utilisés pour aider à améliorer la qualité de vie sexuelle.
La consultation de médecine sexuelle va permettre aux patients de trouver des solutions adaptées. Le médecin prend en compte les besoins de chaque patient en matière de santé sexuelle. Des solutions sont toujours possibles afin d'améliorer la qualité de vie sexuelle et donc la qualité de vie en général.


Consultations individuelles (2) par un médecin spécialisé en sexologie dont le dépassement d’honoraires sera intégralement pris en charge par l’association ISIS.

Patients concernés : hommes bénéficiant d’un traitement sur la PROSTATE, la VESSIE ou le RECTUM.

Lieu : 4 rue des Etats Unis, Cannes.

Psychology

Psychological follow-up is an integral part of the overall care of people affected by cancer. Its psychological consequences can affect self-esteem, relationships with others and quality of life. Psychological support can be beneficial for patients as well as for their family and caregivers. The psychologist is there to help patients manage their emotions and the stress induced by the announcement of the cancer, to better understand the physical and psychological effects of the disease, and to find ways to support the relatives. Psychological follow-up is open to all those who feel the need.

Hairstyle and hair prosthesis

Hair loss is a common side effect of chemotherapy treatments. However, there are options to help patients regain their confidence and improve their quality of life. The hair stylist and the hair prosthetist can help you through this difficult stage to better cope with the side effects of certain chemotherapies. Different, complementary approaches are available to you:

• The socio-coiffeur is trained to accompany and bring patients well-being, comfort and solutions for a better self-esteem: cutting your hair, color, specific care.

• The medical hair stylist offers hair prosthesis models (wigs) made from high quality synthetic or natural fibers. They are designed to be comfortable to wear and easy to maintain. They can be adapted to the shape of the head and the natural hair color. Health insurance companies will cover the cost of the headgear depending on its composition.

• Scarves, headbands and hats can also be offered.

Osteopathy

Osteopathy is a therapeutic approach that can help patients manage the side effects of illness and treatment. It treats joint pain and stiffness, relieving muscle tension and improving blood flow. It can also help reduce fatigue and pain induced by the disease. Osteopathy is tailored to each individual according to their needs and abilities. Consultations are done with a qualified osteopath who is familiar with the issues related to cancer. He or she will be able to develop a treatment plan that is adapted to the individual. Osteopathy can be practiced at any stage of the disease with the agreement of your Oncologist.

Foot reflexology

Reflexology is a natural medicine method that consists of applying pressure to reflex zones on the feet.

It helps to alleviate stress by providing general relaxation, revitalizing the body while strengthening the immune system, improving blood circulation, facilitating the elimination functions of the body, helping treat a large number of minor ailments of everyday life, and helping the body to find its balance.

Reflexology is an ancient natural technique providing benefits for over 5000 years.

The foot is a miniature representation of the human body. Each reflex zone corresponds to an organ, a gland, or a part of the body. A specific touch on these zones allows for restoring the balance in the corresponding parts of the body. Its goal is to stimulate the body's self-healing mechanisms to restore and maintain homeostasis (natural balance of the body).

Foot reflexology considers the individual as a whole. It accompanies a treatment and prevents and maintains good health.

CONTRA-INDICATIONS
The reflexologist cannot intervene in the case of :
- Thrombophlebitis
- Fracture and sprain of the foot
- Pregnancy: during the first 3 months

Socio-cosmetic care

Socio-cosmetic care promotes healing through communication, wellness, and holistic care for people with cancer. It can help manage the physical and psychological side effects of the disease and treatments. They may include services such as massage, skincare, and makeup. These services can help patients feel better about their bodies and improve their self-esteem. This care allows all patients to take time for themselves, relax, and accept the disease gently. This care can also help manage the disease's side effects such as fatigue, pain, and stress.

Adapted Physical Activity

Adapted physical activities are an effective way to manage the side effects of cancer treatment and enhance physical and mental well-being. They can be done at any stage of the disease, and are tailored to the needs and abilities of each individual. These activities can help improve muscle strength, endurance, flexibility, and quality of life. They can also help reduce fatigue, anxiety, and depression, and improve sleep.
The goal is to develop a safe and effective exercise plan that will suit your needs. Adapted physical activity is an excellent way to care for yourself during and after cancer treatment. APA helps fight recurrence and improves patients' quality of life. It is a way to feel more robust, and more in control of your body and mind.

Physical activity is practiced indoors and/or outdoors.

Financial participation is required: 15€/month for 1 weekly class and 21€/month for 2 weekly classes.

Art therapy

Art therapy is a therapeutic approach that can help cancer patients manage their anxiety and stress by making their physical and psychological emotions visible through creativity and images.

It allows us to make visible and give voice to often indescribable emotions and experiences through artistic expression. It helps to discover oneself, bring out past or present traumas, stimulate creativity, and replace negative inner images with positive images of peace and serenity.

Art therapy can help increase understanding of oneself, the disease, and its treatment, promoting a better acceptance of the disease.

Medical Dermopigmentation

Medical dermopigmentation is an innovative technique that can help cancer patients regain their self-confidence and live better with the side effects of chemotherapy treatments: eyebrow alopecia.

Using special pigments, medical dermopigmentation professionals can help patients mask the loss of eyebrows caused by chemotherapy. The dermographer can help patients regain their original appearance and feel better about themselves.

Medical tattooing is performed by trained and qualified healthcare professionals who use high-quality pigments to replicate the colors and shades of the skin. This ensures visibly natural results, which will fade to make way for natural eyebrow regrowth.

Dietetics nutrition

Diet and nutrition are important aspects of the overall management of people with cancer. Proper nutrition can help manage the physical and psychological effects of the disease and treatments. A qualified dietitian-nutritionist helps patients develop a meal plan that is tailored to their individual needs, taking into account their health status, treatment, and food preferences. She can also help manage the side effects of the disease such as weight loss, fatigue, and nausea. A balanced, nutrient-rich diet can help maintain overall health and reduce the risk of disease-related complications.

Two types of appointments are supported by ISIS:
- 1-2 30' one-on-one appointments to address general day-to-day questions and concerns.
- 1 to 2 consultations to determine a personalized nutrition plan after a thorough assessment.

Yoga

Regular yoga practice can help improve the quality of life for cancer patients by reducing the side effects of the disease and treatments, improving physical strength, and increasing the ability to manage emotions.

Yoga postures can help improve flexibility, muscle strength, breathing, and blood circulation. Relaxation techniques such as meditation and breathing can help reduce anxiety and depression. Yoga classes for people with cancer are taught by qualified teachers who are familiar with the side effects of the disease and can adapt the postures and exercises to suit each patient.

Sexual health

Sexual health is an important aspect of comprehensive cancer care. Patients can be affected by the physical and psychological effects of the disease and treatment, which can impact their sex lives.
Regardless of cancer, and regardless of the stage of the disease and its treatment, intimate and sexual life can be disrupted. Addressing sexual dysfunction is an integral part of the medical approach to treating an individual and not just a diseased organ.
It is important that patients are informed about the possible effects of the disease and treatment on their sex life, and that resources are available to help them manage these effects.
Sex therapy and medications can be used to help improve the quality of sexual life.
The sexual medicine consultation will help patients find appropriate solutions. The physician will consider the sexual health needs of each patient. Solutions are always possible in order to improve the quality of sexual life and therefore the quality of life in general.


Individual consultations (2) by a doctor specialized in sexology whose fees will be fully covered by the ISIS association.

Patients concerned: men undergoing treatment for PROSTATE, VESSIA, or RECTUM.

Location: 4 rue des Etats Unis, Cannes.